A5056700046- Immune cells in cancer
- Cancer Cells and Metastasis
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- PARP inhibition in cancer therapy
- Toxin Mechanisms and Immunotoxins
- Immune Response and Inflammation
- Cancer, Hypoxia, and Metabolism
- Multiple Myeloma Research and Treatments
- vaccines and immunoinformatics approaches
Hokkaido University
2020-2023
Interleukin-34 (IL-34) is an alternative ligand to colony-stimulating factor-1 (CSF-1) for the CSF-1 receptor that acts as a key regulator of monocyte/macrophage lineage. In this study, we show tumor-derived IL-34 mediates resistance immune checkpoint blockade regardless existence in various murine cancer models. Consistent with its immunosuppressive characteristics, expression tumors correlates decreased frequencies cellular (such CD8+ and CD4+ T cells M1-biased macrophages) molecular...
Breast cancer susceptibility gene 1 (BRCA1)-associated ovarian patients have been treated with A poly (ADP-ribose) polymerase (PARP) inhibitor, extending the progression-free survival; however, they finally acquire therapeutic resistance. Interleukin (IL)-34 has reported as a poor prognostic factor in several cancers, including cancer, and it contributes to resistance of chemotherapies. IL-34 may affect effect PARP inhibitor through regulation tumor microenvironment (TME).In this study, The...
Among cancer immunotherapy, which has received great attention in recent years, vaccines can potentially prevent recurrent tumors by using the exquisite power and specificity of immune system. Specifically, whole tumor cell (WTCVs) based on surgically resected have been considered to elicit robust anti-tumor responses exposing various tumor-associated antigens host immunity. However, most little immunogenicity because immunoediting continuous interactions with immunity; thus, preparing WTCVs...